|
WO2009124399A1
|
|
Inhibition of cell migration by a farnesylated dibenzodiazepinone
|
|
US2009170837A1
|
|
Methods for treating ras driven cancer in a subject
|
|
US2009062255A1
|
|
Tumor-targeting evaluation methodology and compounds related thereto
|
|
US2008161291A1
|
|
Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
|
|
WO2008010980A2
|
|
Tat-049 and methods of assessing and treating cancer
|
|
EP2035037A2
|
|
Methods, compositions, and kits for treating shiga toxin associated conditions
|
|
US2009258010A1
|
|
Methods, compositions, and kits for treating shiga toxin associated conditions
|
|
WO2007131365A1
|
|
Treatment of neoplastic disorders using a farnesyl dibenzodiazepinone administered by continuous intravenous infusion
|
|
CN101495616A
|
|
Process for producing farnesylated dibenzodiazepinone by fermentation
|
|
CN101541327A
|
|
Crystalline forms of a farnesyl dibenzodiazepinone
|
|
US2007078112A1
|
|
Phosphate prodrugs of a farnesyl dibenzodiazepinone, processes for their production and their use as pharmaceuticals
|
|
EP1809612A1
|
|
Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
|
|
US2006079508A1
|
|
Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions
|
|
US2005038090A1
|
|
Polyene oxazoles and processes for their preparation
|
|
EP1585752A1
|
|
Polyene polyketides, processes for their production and their use as a pharmaceutical
|
|
US7257562B2
|
|
High throughput method for discovery of gene clusters
|
